High tumour antigen (TAA) availability due to a high tumour mutational burden (TMB) or microsatellite instability (MSI) has also been associated with ICPI responsiveness, and checkpoint expression on activated, antigen-exposed immune cells, along with PD-L1 on tumour cells, provide targets for ICPI therapy (12). The gene discussed is CD274; the disease is neoplasm.